<ul data-eligibleForWebStory="true"><li>British HealthTech startup Laverock Therapeutics, focused on gene control tech development, increases its Seed funding round to over €23.3 million.</li><li>The investment, led by Calculus Capital, with participation from existing and new investors, will support technology validation, therapeutic program development, and partnerships.</li><li>Laverock utilizes programmable gene control technology to develop disease-responsive therapies with enhanced precision and safety profiles.</li><li>The company's recent advancements include positive functional data in cancer models, aiming to transform the efficacy and safety of advanced therapies.</li></ul>

London-based startup Laverock Therapeutics raises over €23.3 million for its gene control tech

Discover more